Personal information

Clinical oncology, Immunology, Translational Oncology, cancer vaccines , clinical trial, metronomic
Italy

Biography

Education- Dr. Correale gained his Medical Degree at the “Federico II” University Medical School in Naples on July 25th, 1988 with the highest score. At the same University, he obtained his PhD (doctorate) in Experimental Oncology (October 1994) and his Clinical Oncology Specialty Diplomas (October 1996) with the highest score.
He passed the final test of the "Management Training Course for Healthcare Managers" University of Calabria Department of Business and Legal Sciences on March 2019
He attended at the " First Calabria Region Training Course on the development of clinical networks" by the : Commercial University “Luigi Bocconi” completed on feb, 18th, 2021
He passed the final test of the "Advanced Training Course for the Management of Healthcare Companies" University of Calabria Department of Business and Legal Sciences on July, 25th,2022.
He gained his II Level Master in "Health Management and Law" at the University of Calabria, Department of Business and Legal Sciences on March 7th 2023.
Career - On August 1993, he became a guest researcher at the laboratory of Immunology, Biochemistry and Immunopharmacology, National Institute of Allergy and Immune Disease, National Institute of Health (NIH), Bethesda, MD, USA” under the supervision of Dr. Michail Sitkowsky. Subsequently, on August 1994, he started his Fogarty Fellowship at the “Laboratory of Tumour Immunology and Biology, Experimental Oncology Section, National Cancer Institute (NCI), NIH, Bethesda, MD, USA”, directed by Dr. Jeffrey Schlom under the supervision of Dr. K Y Tsang.
On March 1998, Dr. Correale was hired as a Medical Staff Member of the Medical Oncology Division at the Siena University School of Medicine where, since September 1st, 2004, he received the Professional role of Translational Immune-Oncology Specialist and Contract Professor in Oncology of either Medical School and Medical Oncology Specialty Program.
On August 2012, he became Staff Member of the Radiotherapy Unit, Department of Medicine, Surgery and Neuroscience, at the Siena University School of Medicine maintaining his responsibility concerning the Translational Immune-Oncology role and Contract Professor in Oncology.
On March 27th .2017 he became the new Director of the Medical Oncology Unit at the "Melacrino-Bianchi-Morelli" Metropolitan Hospital in Reggio Calabria.
Scientific and clinical interest- Dr Correale is a clinician with laboratory expertise in the field of cancer immunology, translational oncology and clinical research on colon and lung cancer medical treatment.
He is the principal investigator and group leader involved in several preclinical and clinical projects.
He is co-author of six patents regarding peptide based cancer vaccines , immune-enhancers and medical technologies; co-author more than 160 scientific publications some of which with high impact factor, more than 250 congress presentations and a number of lectures in the field of tumour immunology , translational oncology, and biomarkers.

Activities

Employment (6)

Azienda ospedaliera "Bianchi-Melacrino-Morelli": Reggio Calabria, IT

2024-07-20 to present | Oncologist with a High Professional Thoracic Oncology Assignment (Department of Hemato-Oncology and Radiotherapy)
Employment
Source: Self-asserted source
Correale P

Azienda Ospedaliera Bianchi-Melacrino-Morelli: Reggio Calabria, Calabria, IT

2017-03-27 to present | Direttore UOC (Oncologia)
Employment
Source: Self-asserted source
Correale P

Azienda Ospedaliera Universitaria Senese: Siena, Toscana, IT

2012-08-01 to 2016-07-31 | Dirigente medico, Oncoimmunology Specialist UOC Radioterapia (medicine, surgery, neuroscience)
Employment
Source: Self-asserted source
Correale P

Azienda Ospedaliera Universitaria Senese: Siena, Toscana, IT

1998 to 2012 | Dirigente medico; UOC oncologia medica (Oncology)
Employment
Source: Self-asserted source
Correale P

National Cancer Institute: Bethesda, MD, US

1994-08 to 1997-08 | Fogarty Fellow (Clinical Cancer Center, Laboratory of Tumor Immunology and Biology)
Employment
Source: Self-asserted source
Correale P

National Institutes of Health: Bethesda, MD, US

1993 to 1994 | Visiting researcher (Laboratory of Immunopharmacology / NIAID)
Employment
Source: Self-asserted source
Correale P

Education and qualifications (6)

University of Calabria: Rende, Calabria, IT

2020-01 to 2023-03-07 | II Level Master in "Health Management and Law" ( Department of Business and Legal Sciences, University of Calabria)
Education
Source: Self-asserted source
Correale P

University of Calabria: Rende, Calabria, IT

2021-01 to 2023-01-13 | Higher Management Training Class in Healthcare Company Management and Direction. University of Calabria and Calabria Region, Cosenza (one year). (Department of Business and Legal Sciences, University of Calabria)
Education
Source: Self-asserted source
Correale P

University of Calabria: Rende, IT

2018-12-01 to 2019-09-14 | Higher Management Training Course for Healthcare Managers. University of Calabria, Cosenza (One year). ( Department of Business and Legal Sciences, University of Calabria)
Education
Source: Self-asserted source
Correale P

Università degli Studi di Napoli Federico II: Napoli, Campania, IT

1988 to 1996 | Medical Specialty in oncology
Education
Source: Self-asserted source
Correale P

University of Chieti-Pescara: Chieti, Abruzzo, IT

1990 to 1994 | Doctorate in experimental oncology (Dipartimento Oncologico - Università degli Studi di Napoli Federico II (sede consorziata))
Education
Source: Self-asserted source
Correale P

Università degli Studi di Napoli Federico II: Naples, IT

1982 to 1988-06-25 | Medical degree
Education
Source: Self-asserted source
Correale P

Funding (13)

A clinical trial on the TSPP anticancer vaccine to the thymidylate synthase enzyme

2010 to present | Grant
Ministero dell’Istruzione, dell’Università e della Ricerca (ROME, IT)
GRANT_NUMBER:

RF-210-2313550

Source: Self-asserted source
Correale P

Immunogenicity and antitumor activity of Tarmogens® engineered to express TS/PP mini-gene as well as full length thymidylate synthase (TS) proteins and/or other peptides

2009 to 2010 | Contract
Globeimmune (Louisvillle, US)
Source: Self-asserted source
Correale P

A clinical investigation of the antitumor activty of the TSPP cancer vaccine to the thymidylate enzyme

2008 to 2011 | Grant
Fondazione Monte dei Paschi di Siena (Siena, IT)
Source: Self-asserted source
Correale P

Preclinical and clinical immunopharmacology studie aimed to design a protocol of chemoimmunotherapy for colon carcinoma and other gastroenteric malignancies

2008 to 2010 | Grant
Ministero dell’Istruzione, dell’Università e della Ricerca (Rome, IT)
Source: Self-asserted source
Correale P

Biological monitoring of metastatic colon carcinoma patients undergone GOLFIG chemoimunotherapy

2007 to 2008 | Grant
Novartis (Siena, CH)
Source: Self-asserted source
Correale P

Immunobiological, toxicological and theraeutic evaluation of anti-cancer active specific immunotherapy to metallo-proteinases

2004 to 2006 | Grant
University of Siena (Siena, IT)
Source: Self-asserted source
Correale P

Imunochemotherap with high antitumor efficiency : new strategies based on drug induced antigen remodelling and gene silencing

2004 to 2006 | Grant
Ministero degli Affari Esteri e della Cooperazione Internazionale (Rome, IT)
Source: Self-asserted source
Correale P

Clinical development in oncology of a PTH-rP peptide vaccine

2003 to 2005 | Contract
Pevion srl (Bern, CH)
Source: Self-asserted source
Correale P

Immunobiological toxicological and therapeutic evaluation of GC90V based active specific immunotherapy of patients with bone metastases in combinazion with Granulocyte Macrophage–Colony stimulating factor (GM-CSF) and interleukin 2 (IL)-2 , A phase II clinical trial

2001 to 2003 | Grant
University of Siena (Siena, IT)
Source: Self-asserted source
Correale P

Colon cancer biotherapy

1998 to 2000 | Grant
Ministero dell’Istruzione, dell’Università e della Ricerca (Siena, IT)
Source: Self-asserted source
Correale P

Study of the effects of interferon alpha and agents able to modify transmembrane ion fluxes on the sensitivity of tumor cells to immune effectors

1992 to 1993 | Grant
Consiglio Nazionale delle Ricerche (Naples , IT)
Source: Self-asserted source
Correale P

Definition of experimental models to use diffentiating angents aimed to control the growth of caner cells and evaluation of the biologcal meaning of differentiation markers in vitro and in vivo

1989 to 1992 | Grant
Associazione Italiana per la Ricerca sul Cancro (naples, IT)
Source: Self-asserted source
Correale P

Italy/USA joint program on new therapies on neoplasia: New strategies in the treatment of human melanoma: definition of experimental in vitro models for enhancement of tumor cell sensitivity to adoptive immunotherapy

1989 to 1991 | Grant
Istituto Superiore di Sanità (Naples, IT)
Source: Self-asserted source
Correale P